Valuation: Aligos Therapeutics, Inc.

Market Cap 3.46Cr 2.99Cr 2.79Cr 2.56Cr 4.82Cr 329.22Cr 4.9Cr 33Cr 13Cr 165.01Cr 13Cr 13Cr 545.53Cr P/E 2026 *
-0.78x
P/E 2027 * -1.24x
Enterprise Value 10L 9L 8L 7L 13.74L 9.39Cr 13.96L 93.46L 36.68L 4.7Cr 37.03L 36.22L 16Cr EV / Sales 2026 *
0.04x
EV / Sales 2027 * -43.9x
Free-Float
77.01%
Yield 2026 *
-
Yield 2027 * -
1 day+1.45%
1 week+32.15%
Current month+32.15%
1 month-8.21%
3 months-7.30%
6 months-23.63%
Current year-40.02%
1 week 4.18
Extreme 4.18
6.15
1 month 3.98
Extreme 3.98
7.08
Current year 3.98
Extreme 3.98
10.49
1 year 3.98
Extreme 3.98
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 05/02/2018
Director of Finance/CFO 60 01/06/2020
Chief Tech/Sci/R&D Officer 65 01/05/2018
Director TitleAgeSince
Director/Board Member 64 01/08/2018
Director/Board Member 74 01/08/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap.
09/03/26 Free

Chief Financial Officer

37,485 0.7002%
29/01/26 Other

Controller/Auditor

17,195 0.3212%
16/07/25 Free

Chief Financial Officer

40,185 1.1600%
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%+32.15%-31.24%-75.02% 3.46Cr
+0.99%+1.78%+4.07%+16.73% 4.95TCr
+3.71%+9.40%+486.98%+592.14% 4.36TCr
+5.60%+10.21%+16.76%+85.72% 3.96TCr
+2.70%+1.57%+33.39%+8.85% 3.93TCr
+2.21%+6.75%+21.31%+53.37% 3.24TCr
+2.23%+4.71% - - 1.68TCr
+0.97%+2.35%+37.75%+126.84% 1.65TCr
-0.11%+2.41%+6.24%+18.87% 1.4TCr
+0.75%+15.04%+78.59%+30.30% 1.28TCr
Average +2.05%+8.90%+72.65%+95.31% 2.65TCr
Weighted average by Cap. +2.54%+6.10%+104.24%+140.76%

Financials

2026 *2027 *
Net sales 2.73Cr 2.37Cr 2.21Cr 2.03Cr 3.81Cr 260.29Cr 3.87Cr 26Cr 10Cr 130.46Cr 10Cr 10Cr 431.31Cr 60L 51.9L 48.47L 44.46L 83.63L 57Cr 84.95L 5.69Cr 2.23Cr 29Cr 2.25Cr 2.2Cr 95Cr
Net income -8.25Cr -7.13Cr -6.66Cr -6.11Cr -11Cr -784.84Cr -12Cr -78Cr -31Cr -393.38Cr -31Cr -30Cr -1.3TCr -13Cr -11Cr -10Cr -9.39Cr -18Cr -1.21TCr -18Cr -120.07Cr -47Cr -604.35Cr -48Cr -47Cr -2TCr
Net Debt -3.36Cr -2.91Cr -2.71Cr -2.49Cr -4.68Cr -319.83Cr -4.76Cr -32Cr -13Cr -160.31Cr -13Cr -12Cr -529.97Cr -30Cr -26Cr -24Cr -22Cr -42Cr -2.84TCr -42Cr -282.59Cr -110.92Cr -1.42TCr -111.97Cr -109.52Cr -4.7TCr
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
07/26/07 $5.590 +1.45% 3,35,793
06/26/06 $5.510 +16.24% 2,93,475
05/26/05 $4.740 -0.21% 71,830
04/26/04 $4.750 +3.26% 81,446
03/26/03 $4.600 +8.75% 1,34,966
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.590USD
Average target price
56.29USD
Spread / Average Target
+906.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock